EGX-A is a serotonin 5-HT_2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders.^[2][3] It acts as a full agonist of the serotonin 5-HT_2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT_2A receptor over the serotonin 5-HT_2B receptor, is much more potent as a serotonin 5-HT_2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents.^[3] The drug is being developed by atai Life Sciences and EntheogeniX Biosciences.^[2] As of January 2024, it is in the preclinical research stage of development.^[2]

• List of investigational hallucinogens and entactogens
• List of investigational antidepressants

• Data from our novel EGX series shows translational antidepressant-like effects, similar to those seen with psilocybin - atai Life Sciences (November 21, 2023) - LinkedIn

This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information.

• v
• t
• e